The potential reassessment of cannabinoids, particularly at the federal level, is generating considerable anticipation within the industry. A shift away from Schedule I status, often viewed as outdated and hindering https://bookmarkspedia.com/story6391043/pot-rescheduling-a-growth-catalyst